Shionogi, Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 766
- Registration Number
- NCT00788528
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 842
- Registration Number
- NCT00748605
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 724
- Registration Number
- NCT00747929
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 919
- Registration Number
- NCT00729469
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 303
- Registration Number
- NCT00723190
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 209
- Registration Number
- NCT00703573
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 37
- Registration Number
- NCT00697710
- Locations
- 🇺🇸
Comprehensive Phase One, Miramar, Florida, United States
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 126
- Registration Number
- NCT00630539
A Clinical Study to Evaluate the Safety of Ospemifene
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 426
- Registration Number
- NCT00566982
Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 137
- Registration Number
- NCT00491894
- Locations
- 🇺🇸
The Children's Center, Bethany, Oklahoma, United States
🇺🇸Rocky Mountain Pediatrics, Lakewood, Colorado, United States
🇺🇸Child Neurology Associates, PC, Atlanta, Georgia, United States
© Copyright 2024. All Rights Reserved by MedPath